intestinal absorption of glucose Inhibitors
1 drugsAbout intestinal absorption of glucose
Intestinal absorption of glucose is a key physiological process involving glucose uptake from the small intestine into the bloodstream. This process is tightly regulated and can become dysregulated in metabolic disorders like diabetes, impacting blood sugar levels.
Modulating intestinal glucose absorption is a therapeutic strategy for managing blood sugar and improving outcomes in metabolic diseases. Currently, there is no genetic evidence directly linking this target to specific diseases.
There is one FDA-approved drug, XIGDUO XR (AstraZeneca), targeting intestinal glucose absorption for metabolic indications. This drug is a small molecule, representing 100% of the modality landscape for this target.
Top intestinal absorption of glucose Drugs
AstraZeneca is the only company with an approved drug targeting intestinal glucose absorption.
The market is highly concentrated, presenting a high barrier to entry unless a differentiated product can be developed.
intestinal absorption of glucose Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets intestinal absorption of glucose, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies and potentially improve efficacy.
intestinal absorption of glucose Clinical Trials 422 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on intestinal absorption of glucose. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 68 | 52 | 5 | 11 | 91% |
| Phase 2 | 96 | 45 | 12 | 39 | 79% |
| Phase 3 | 116 | 73 | 3 | 39 | 96% |
| Phase 4 | 142 | 90 | 13 | 38 | 87% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved intestinal absorption of glucose drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting intestinal absorption of glucose. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
intestinal absorption of glucose Drug Approval Timeline (2014 - 2014)
The first and only drug, XIGDUO XR, was approved in 2014.
The approval timeline indicates a potentially unsaturated market, but also a lack of recent innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 206 (27 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on intestinal absorption of glucose. A trial counts if an approved drug acting on intestinal absorption of glucose is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.